Autologous tumor rejection in humans

Trimming the myths

Ena Wang, Monica Panelli, Francesco M. Marincola

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

There is overwhelming evidence that the human immune system can keep in check the growth of autologous tumors. Yet, this phenomenon is rare and most often tumors survive striking a balance with the host's immune system. The well-documented coexistence of immune cells that can recognize cancer and their targets within the same host is reminiscent of chronic allograft rejection well-controlled by immune suppression or of a lingering tissue-specific autoimmune reaction. In this review, we argue that autologous tumor rejection represents a distinct form of tissue-specific rejection similar to acute allograft rejection or to flares of autoimmunity. Here we discuss similarities within the biology of these phenomena that may converge into a common immunological constant of rejection. The purpose is to simplify the basis of immune rejection to its bare bones critically dissecting the significance of those components proposed by experimental models as harbingers of this final outcome.

Original languageEnglish
Pages (from-to)437-458
Number of pages22
JournalImmunological Investigations
Volume35
Issue number3-4
DOIs
Publication statusPublished - 1 Dec 2006
Externally publishedYes

Fingerprint

Allografts
Immune System
Neoplasms
Autoimmunity
Theoretical Models
Bone and Bones
Growth

Keywords

  • Basal cell carcinoma
  • Epstein-Barr virus
  • Immunization Immunotherapy/interleukin-2/melanoma
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Immunology

Cite this

Autologous tumor rejection in humans : Trimming the myths. / Wang, Ena; Panelli, Monica; Marincola, Francesco M.

In: Immunological Investigations, Vol. 35, No. 3-4, 01.12.2006, p. 437-458.

Research output: Contribution to journalReview article

Wang, Ena ; Panelli, Monica ; Marincola, Francesco M. / Autologous tumor rejection in humans : Trimming the myths. In: Immunological Investigations. 2006 ; Vol. 35, No. 3-4. pp. 437-458.
@article{c509570d307349e4884bc24605abff92,
title = "Autologous tumor rejection in humans: Trimming the myths",
abstract = "There is overwhelming evidence that the human immune system can keep in check the growth of autologous tumors. Yet, this phenomenon is rare and most often tumors survive striking a balance with the host's immune system. The well-documented coexistence of immune cells that can recognize cancer and their targets within the same host is reminiscent of chronic allograft rejection well-controlled by immune suppression or of a lingering tissue-specific autoimmune reaction. In this review, we argue that autologous tumor rejection represents a distinct form of tissue-specific rejection similar to acute allograft rejection or to flares of autoimmunity. Here we discuss similarities within the biology of these phenomena that may converge into a common immunological constant of rejection. The purpose is to simplify the basis of immune rejection to its bare bones critically dissecting the significance of those components proposed by experimental models as harbingers of this final outcome.",
keywords = "Basal cell carcinoma, Epstein-Barr virus, Immunization Immunotherapy/interleukin-2/melanoma, Renal cell carcinoma",
author = "Ena Wang and Monica Panelli and Marincola, {Francesco M.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1080/08820130600762385",
language = "English",
volume = "35",
pages = "437--458",
journal = "Immunological Investigations",
issn = "0882-0139",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Autologous tumor rejection in humans

T2 - Trimming the myths

AU - Wang, Ena

AU - Panelli, Monica

AU - Marincola, Francesco M.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - There is overwhelming evidence that the human immune system can keep in check the growth of autologous tumors. Yet, this phenomenon is rare and most often tumors survive striking a balance with the host's immune system. The well-documented coexistence of immune cells that can recognize cancer and their targets within the same host is reminiscent of chronic allograft rejection well-controlled by immune suppression or of a lingering tissue-specific autoimmune reaction. In this review, we argue that autologous tumor rejection represents a distinct form of tissue-specific rejection similar to acute allograft rejection or to flares of autoimmunity. Here we discuss similarities within the biology of these phenomena that may converge into a common immunological constant of rejection. The purpose is to simplify the basis of immune rejection to its bare bones critically dissecting the significance of those components proposed by experimental models as harbingers of this final outcome.

AB - There is overwhelming evidence that the human immune system can keep in check the growth of autologous tumors. Yet, this phenomenon is rare and most often tumors survive striking a balance with the host's immune system. The well-documented coexistence of immune cells that can recognize cancer and their targets within the same host is reminiscent of chronic allograft rejection well-controlled by immune suppression or of a lingering tissue-specific autoimmune reaction. In this review, we argue that autologous tumor rejection represents a distinct form of tissue-specific rejection similar to acute allograft rejection or to flares of autoimmunity. Here we discuss similarities within the biology of these phenomena that may converge into a common immunological constant of rejection. The purpose is to simplify the basis of immune rejection to its bare bones critically dissecting the significance of those components proposed by experimental models as harbingers of this final outcome.

KW - Basal cell carcinoma

KW - Epstein-Barr virus

KW - Immunization Immunotherapy/interleukin-2/melanoma

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33747600615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747600615&partnerID=8YFLogxK

U2 - 10.1080/08820130600762385

DO - 10.1080/08820130600762385

M3 - Review article

VL - 35

SP - 437

EP - 458

JO - Immunological Investigations

JF - Immunological Investigations

SN - 0882-0139

IS - 3-4

ER -